RANDOMIZED PHASE III STUDY TO EVALUATE THE VALUE OF rHuG-CSF IN INDUCTION AND OF AN ORAL SCHEDULE AS CONSOLIDATION TREATMENT IN ELDERLY PATIENTS WITH ACUTE MYELOGENOUS LEUMEKIA (AML-13 PROTOCOL)
The EORTC's AML-13 trial evaluates the efficacy of rHuG-CSF in combination with chemotherapy for elderly patients with acute myeloid leukemia (AML). Given the aging population and the increasing incidence of AML, this study addresses a significant unmet medical need. The results could position rHuG-CSF as a critical adjunct therapy in AML treatment regimens, potentially enhancing market share for the sponsor and collaborators. The competitive landscape includes other G-CSF formulations and alternative therapies, necessitating a thorough analysis of clinical outcomes and market positioning. Diligence should focus on the trial's results and subsequent regulatory pathways for commercialization.
Indication: Leukemia
Modality: protein therapy
Target: Granulocyte Colony-Stimulating Factor (G-CSF)
Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jun 25, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Granulocyte Colony-Stimulating Factor (G-CSF)
View original source fields
Condition raw: Leukemia, Neutropenia
Condition normalized: Leukemia, Neutropenia
Modality raw: protein therapy
Modality normalized: protein therapy
Target raw: Granulocyte Colony-Stimulating Factor (G-CSF)
Target normalized: Granulocyte Colony-Stimulating Factor (G-CSF)